Nurix Therapeutics (NRIX) Competitors $12.55 -0.18 (-1.41%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$12.53 -0.02 (-0.19%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. RNA, ACLX, OGN, ZLAB, RARE, SWTX, AKRO, ALVO, RYTM, and MRUSShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Rhythm Pharmaceuticals (RYTM), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Avidity Biosciences Arcellx Organon & Co. Zai Lab Ultragenyx Pharmaceutical SpringWorks Therapeutics Akero Therapeutics Alvotech Rhythm Pharmaceuticals Merus Nurix Therapeutics (NASDAQ:NRIX) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership. Does the MarketBeat Community favor NRIX or RNA? Avidity Biosciences received 86 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 77.88% of users gave Nurix Therapeutics an outperform vote while only 69.01% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformNurix TherapeuticsOutperform Votes8177.88% Underperform Votes2322.12% Avidity BiosciencesOutperform Votes16769.01% Underperform Votes7530.99% Is NRIX or RNA more profitable? Nurix Therapeutics has a net margin of -354.85% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-354.85% -53.65% -38.59% Avidity Biosciences -2,772.45%-27.66%-24.56% Do analysts rate NRIX or RNA? Nurix Therapeutics presently has a consensus price target of $30.88, suggesting a potential upside of 146.07%. Avidity Biosciences has a consensus price target of $66.69, suggesting a potential upside of 104.83%. Given Nurix Therapeutics' higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, NRIX or RNA? Nurix Therapeutics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M17.46-$193.57M-$2.89-4.34Avidity Biosciences$10.90M359.19-$212.22M-$2.89-11.27 Which has more risk and volatility, NRIX or RNA? Nurix Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Does the media favor NRIX or RNA? In the previous week, Avidity Biosciences had 10 more articles in the media than Nurix Therapeutics. MarketBeat recorded 20 mentions for Avidity Biosciences and 10 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.05 beat Avidity Biosciences' score of 0.71 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNurix Therapeutics beats Avidity Biosciences on 9 of the 15 factors compared between the two stocks. Remove Ads Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$952.38M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-4.347.2023.1719.03Price / Sales17.46226.01385.1993.17Price / CashN/A65.6738.1634.64Price / Book1.696.476.944.33Net Income-$193.57M$141.90M$3.20B$247.06M7 Day Performance-3.39%-3.20%-2.29%-0.37%1 Month Performance-18.77%-5.64%2.88%-3.85%1 Year Performance-14.63%-7.47%10.82%1.27% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.0442 of 5 stars$12.55-1.4%$30.88+146.1%-13.7%$952.38M$54.55M-4.34300RNAAvidity Biosciences2.3299 of 5 stars$33.30+8.0%$66.69+100.3%+32.0%$4.00B$10.90M-11.56190ACLXArcellx2.2681 of 5 stars$72.48+4.5%$108.46+49.6%-2.8%$3.98B$107.94M-102.0880Positive NewsOGNOrganon & Co.4.7867 of 5 stars$15.35-0.3%$20.80+35.5%-21.1%$3.96B$6.40B4.6110,000News CoveragePositive NewsZLABZai Lab2.426 of 5 stars$35.67+1.7%$47.37+32.8%+123.5%$3.91B$398.99M-12.881,950Analyst ForecastRAREUltragenyx Pharmaceutical4.4597 of 5 stars$39.36+0.5%$91.71+133.0%-16.9%$3.64B$560.23M-6.211,276Analyst ForecastNews CoverageSWTXSpringWorks Therapeutics2.3976 of 5 stars$48.51-2.8%$73.20+50.9%-5.2%$3.64B$191.59M-13.94230Positive NewsAKROAkero Therapeutics4.2732 of 5 stars$45.08-0.3%$76.29+69.2%+78.2%$3.59BN/A-12.0230Insider TradeALVOAlvotech2.008 of 5 stars$11.56-0.1%$18.00+55.7%-18.3%$3.49B$391.87M-6.251,026Earnings ReportNews CoverageRYTMRhythm Pharmaceuticals4.4416 of 5 stars$53.72+3.2%$69.46+29.3%+28.0%$3.40B$130.13M-12.41140Analyst RevisionMRUSMerus2.3839 of 5 stars$48.77+3.2%$85.31+74.9%+0.2%$3.37B$36.13M-12.3537 Remove Ads Related Companies and Tools Related Companies RNA Alternatives ACLX Alternatives OGN Alternatives ZLAB Alternatives RARE Alternatives SWTX Alternatives AKRO Alternatives ALVO Alternatives RYTM Alternatives MRUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
